Login to Your Account

Other News To Note

Thursday, February 7, 2013
• Oxygen Biotherapeutics Inc., of Morrisville, N.C., said it signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research at Fort Sam Houston, Texas, to explore the potential effects of the firm's perfluorocarbon-based emulsion, Oxycyte, on platelet function and blood hemostasis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription